Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Clinical trial NCT06038539 · TERMINATED

Trial details

NCT number: NCT06038539
Sponsor: Biocon Biologics UK Ltd
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Start date: 2025-01-06
Primary completion: 2025-12-23
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.